Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Revenue | 26.73 | 26.89 | 14.60 | 14.09 |
Total Revenue | 26.73 | 26.89 | 14.60 | 14.09 |
Costof Revenue Total | 13.15 | 14.54 | 8.40 | 7.42 |
Gross Profit | 13.58 | 12.35 | 6.20 | 6.67 |
Selling/ General/ Admin Expenses Total | 1.93 | 1.70 | 1.31 | 1.18 |
Depreciation/ Amortization | 1.20 | 0.80 | 1.07 | 1.25 |
Other Operating Expenses Total | 9.38 | 8.71 | 4.48 | 4.05 |
Total Operating Expense | 25.65 | 25.76 | 15.28 | 13.92 |
Operating Income | 1.08 | 1.13 | -0.68 | 0.17 |
Interest Inc( Exp) Net- Non- Op Total | -4.64 | -4.16 | -3.97 | 0.25 |
Other Net | 0.40 | 0.27 | 0.12 | 0.15 |
Net Income Before Taxes | 1.01 | 0.98 | -0.95 | 0.35 |
Provisionfor Income Taxes | 0.24 | 0.22 | -0.29 | 0.11 |
Net Income After Taxes | 0.77 | 0.77 | -0.66 | 0.24 |
Net Income Before Extra Items | 0.77 | 0.77 | -0.66 | 0.24 |
Net Income | 0.77 | 0.77 | -0.66 | 0.24 |
Income Availableto Com Excl Extra Ord | 0.77 | 0.77 | -0.66 | 0.24 |
Income Availableto Com Incl Extra Ord | 0.77 | 0.77 | -0.66 | 0.24 |
Diluted Net Income | 0.77 | 0.77 | -0.66 | 0.24 |
Diluted Weighted Average Shares | 0.51 | 0.51 | 0.51 | 0.51 |
Diluted EPS Excluding Extra Ord Items | 1.52 | 1.51 | -1.30 | 0.47 |
Diluted Normalized EPS | 1.52 | 1.51 | -1.30 | 0.47 |
Interest Exp( Inc) Net- Operating Total | - | 0.13 | 0.16 | 0.20 |
Total Adjustmentsto Net Income | - | 0.00 | - | - |
Dilution Adjustment | - | 0.00 | - | - |
Beryl Drugs Dividend Beryl Drugs Bonus Beryl Drugs News Beryl Drugs AGM Beryl Drugs Rights Beryl Drugs Splits Beryl Drugs Board Meetings Beryl Drugs Key Metrics Beryl Drugs Shareholdings Beryl Drugs Balance Sheet Beryl Drugs Cashflow Beryl Drugs Q1 Results Beryl Drugs Q2 Results Beryl Drugs Q3 Results Beryl Drugs Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks